Results 11 to 20 of about 32,704 (143)

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.

New England Journal of Medicine, 2022
BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life.
L. Hammitt, R. Dagan, Yuan Yuan, M. Baca Cots, M. Bosheva, S. Madhi, W. Muller, H. Zar, Dennis Brooks, Amy Grenham, U. Wählby Hamrén, V. S. Mankad, P. Ren, Therese Takas, M. Abram, A. Leach, M. P. Griffin, T. Villafana   +17 more
semanticscholar   +1 more source

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

Nature Network Boston, 2023
The prolonged persistence at elevated levels of nirsevimab, an RSV-specific monoclonal antibody, likely accounts for the observed protection from severe disease throughout an RSV season, while it does not prevent the induction of a natural immune ...
Deidre Wilkins, Yuan Yuan, Yue Chang, A. Aksyuk, Beatriz Seoane Núñez, U. Wählby-Hamrén, Tianhui Zhang, M. Abram, Amanda Leach, T. Villafana, M. Esser   +10 more
semanticscholar   +1 more source

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)

Pathogens, 2023
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease, especially in young children. Despite its global impact on healthcare, related to its high prevalence and its association with significant morbidity, the ...
D. Gatt, I. Martin, R. Alfouzan, T. Moraes   +3 more
semanticscholar   +1 more source

Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis

Open Forum Infectious Diseases, 2022
Background Adult respiratory syncytial virus (RSV) vaccines are in the late stages of development. A comprehensive synthesis of adult RSV burden is needed to inform public health decision-making. Methods We performed a systematic review and meta-analysis
J. McLaughlin, F. Khan, Elizabeth Begier, D. Swerdlow, L. Jodar, A. Falsey   +5 more
semanticscholar   +1 more source

RSV Prevention in All Infants: Which Is the Most Preferable Strategy?

Frontiers in Immunology, 2022
Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and young children that may lead to hospitalizations and a substantial number of outpatient visits, which result in a huge economic and healthcare burden.
S. Esposito, B. Abu Raya, Eugenio Baraldi, K. Flanagan, F. Martinón Torres, M. Tsolia, S. Zielen   +6 more
semanticscholar   +1 more source

The path to an RSV vaccine [PDF]

Current Opinion in Virology, 2013
Respiratory syncytial virus (RSV) is the greatest remaining unmet infant vaccine need in developed countries and an important unmet infant vaccine need worldwide. More than 40 years of effort have yet to result in a licensed RSV vaccine for humans.
Christine A. Shaw, Paula Keith, Max Ciarlet, Philip R. Dormitzer, Lamberto Dionigi, Brian W. Cooper, Maryam Rafie-Kolpin, Karen B O’Brien   +7 more
openaire   +3 more sources

Nasal Microbiota in RSV Bronchiolitis [PDF]

Microorganisms, 2020
Respiratory Syncytial Virus (RSV) is the leading cause of bronchiolitis, and the severity may be influenced by the bacterial ecosystem. Our aim was to analyze the nasal microbiota from 48 infants affected by bronchiolitis from RSV virus and 28 infants with bronchiolitis but negative for the virus.
Schippa, Serena, Frassanito, Antonella, Marazzato, Massimiliano, Nenna, Raffaella, Petrarca, Laura, Neroni, Bruna, Bonfiglio, Giulia, Guerrieri, Francesca, Frasca, Federica, Oliveto, Giuseppe, Pierangeli, Alessandra, Midulla, Fabio   +11 more
openaire   +5 more sources

Off-season RSV epidemics in Australia after easing of COVID-19 restrictions

Nature Communications, 2021
Human respiratory syncytial virus (RSV) is an important cause of acute respiratory infection with the most severe disease in the young and elderly.
John-Sebastian Eden, C. Sikazwe, Ruopeng Xie, Yi-Mo Deng, Sheena G. Sullivan, Alice Michie, A. Levy, Elena J Cutmore, C. Blyth, P. Britton, N. Crawford, Xiaomin Dong, D. Dwyer, Kimberly M. Edwards, B. Horsburgh, D. Foley, K. Kennedy, C. Minney-Smith, D. Speers, R. Tulloch, E. Holmes, V. Dhanasekaran, David W Smith, J. Kok, I. Barr   +24 more
semanticscholar   +1 more source

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model

Journal of Infectious Diseases, 2022
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an investigational long-acting monoclonal antibody, was evaluated as an immunoprophylactic strategy for ...
A. Kieffer, Matthieu Beuvelet, A. Sardesai, Robert Musci, S. Milev, J. Roiz, Jason K H Lee   +6 more
semanticscholar   +1 more source

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.

Cochrane Database of Systematic Reviews, 2021
BACKGROUND Respiratory viruses are the leading cause of lower respiratory tract infection (LRTI) and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is the main infectious agent in this population.
L. Garegnani, Lea Styrmisdóttir, P. Roson Rodriguez, C. E. Escobar Liquitay, I. Esteban, Juan V A Franco   +5 more
semanticscholar   +1 more source